Alzamend Neuro, Inc.
ALZN
$1.46
$0.000.00%
NASDAQ
| 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 66.68% | 10.76% | -4.98% | 6.72% | -11.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 94.96% | 67.18% | 0.76% | -15.45% | -54.75% |
| Operating Income | -94.96% | -67.18% | -0.76% | 15.45% | 54.75% |
| Income Before Tax | -94.30% | -66.60% | -0.55% | 15.57% | 54.61% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -94.30% | -66.60% | -0.55% | 15.57% | 54.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -94.30% | -66.60% | -0.55% | 15.57% | 54.61% |
| EBIT | -94.96% | -67.18% | -0.76% | 15.45% | 54.75% |
| EBITDA | -94.69% | -66.92% | -0.25% | 15.76% | 55.03% |
| EPS Basic | 84.81% | 83.96% | 90.61% | 90.86% | 85.79% |
| Normalized Basic EPS | 84.17% | 86.47% | 91.88% | 91.65% | 86.36% |
| EPS Diluted | 84.81% | 83.96% | 90.61% | 90.86% | 85.79% |
| Normalized Diluted EPS | 84.17% | 86.47% | 91.88% | 91.65% | 86.36% |
| Average Basic Shares Outstanding | 635.69% | 758.03% | 977.08% | 1,121.65% | 500.03% |
| Average Diluted Shares Outstanding | 635.69% | 758.03% | 977.08% | 1,121.65% | 500.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |